Efficacy and prognosis of neoadjuvant chemotherapy is correlated with breast cancer molecular classification.

No abstract is available for this paper.

• Publication year

  2015

• Venue

  International journal of clinical pharmacology and therapeutics

• Publication date

  2015-02-06

• Fields of study

  Medicine

• Identifiers
  DOI 10.5414/CP202327PMID 25907177
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer

  2015cited by this paper
• Utilization and impact of a postmastectomy radiation boost for invasive breast cancer.

  2014cited by this paper
• Chemo/Dietary prevention of cancer: perspectives in China

  2014cited by this paper
• Current and upcoming approaches to exploit the reversibility of epigenetic mutations in breast cancer

  2014cited by this paper
• Oleanane triterpenoids in the prevention and therapy of breast cancer: current evidence and future perspectives

  2014cited by this paper
• Disparities in hospice utilization among American Indian Medicare beneficiaries dying of cancer.

  2014cited by this paper
• Detection of posteriorly located breast tumors using gold nanoparticles: A breast-mimicking phantom study

  2014cited by this paper
• Metabolic profile of triple-negative breast cancer in African-American women reveals potential biomarkers of aggressive disease.

  2014cited by this paper
• Breast cancer in male-to-female transsexuals: use of breast imaging for detection.

  2014cited by this paper
• Epidemiology, biology, and treatment of triple-negative breast cancer in women of African ancestry.

  2014cited by this paper
• Neoadjuvant chemotherapy in locally advanced breast cancer.

  2014cited by this paper
• Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.

  2014cited by this paper
• Molecular types and neoadjuvant chemotherapy in patients with breast cancer- while molecular shifting is more common in luminal a tumors, the pathologic complete response is most frequently observed in her-2 like tumors.

  2014cited by this paper
• Excellent Biochemical Response to Polychemotherapy with Nab-Paclitaxel/Gemcitabine in an 82-Year-Old Female with Metastatic Breast Cancer

  2014cited by this paper
• Clinical risk factor analysis for breast cancer: 568,000 subjects undergoing breast cancer screening in Beijing, 2009.

  2013cited by this paper
• Molecular subtype can predict the response and outcome of Chinese locally advanced breast cancer patients treated with preoperative therapy.

  2010cited by this paper
• Breast cancer stem cells and intrinsic subtypes: controversies rage on.

  2009cited by this paper
• Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients

  2009cited by this paper
• Identification of tumor-initiating cells in a p53-null mouse model of breast cancer.

  2008cited by this paper
• Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

  2008cited by this paper
• The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer Subtypes

  2007cited by this paper
• Phenotypic evaluation of the basal-like subtype of invasive breast carcinoma

  2006cited by this paper

• The Combination of Immune Checkpoint Blockade with Tumor Vessel Normalization as a Promising Therapeutic Strategy for Breast Cancer: An Overview of Preclinical and Clinical Studies

  2023cites this paper
• Histogram analysis of quantitative parameters from synthetic MRI: Correlations with prognostic factors and molecular subtypes in invasive ductal breast cancer.

  2021cites this paper
• PD-L1 Acts as a Promising Immune Marker to Predict the Response to Neoadjuvant Chemotherapy in Breast Cancer Patients.

  2020cites this paper